Explore more Johnson & Johnson sites:
Share
Celebrating Our Own Champions of Science with the 2020 Johnson Medal
Despite the ongoing pandemic, the scientists and engineers across Johnson & Johnson continue to work to advance transformational innovations to meet unmet healthcare needs for customers and patients across the world. This November, 21 outstanding innovators across our Consumer Health, Medical Devices and Pharmaceutical sectors were honored with the 2020 Johnson Medal for Research and Development—the most prestigious award given for R&D excellence within Johnson & Johnson. This year’s winning teams were honored for the development of Aveeno® Absolutely Ageless™ Blackberry Complex, EMBOTRAP® II Revascularization Device, SURGICEL® Powder Absorbable Hemostat and TREMFYA® (guselkumab). These resilient teams have demonstrated remarkable ingenuity, perseverance and collaboration to bring forward innovations that are now enhancing the health of people all over the world.
Aveeno® Absolutely Ageless™ Blackberry Complex
Sheer perseverance and ingenuity paid off for this team of motivated researchers at J&J Consumer Health as they overcame obstacles to advance our deep understanding of skin health and harness a unique combination of ingredients to create the Blackberry Complex: a new, proprietary technology to fight multiple signs of skin aging and deliver on unmet consumer needs.
-
ON NOW
Anne-Sophie Brillouet, Senior Director, Consumer HealthAnne-Sophie Brillouet, Senior Director, Consumer Health -
ON NOW
Marisa Dufort, Director, Consumer Health R&DMarisa Dufort, Director, Consumer Health R&D -
ON NOW
Simarna Kaur, Ph.D., Research Manager, Skin Health, Consumer Health R&DSimarna Kaur, Ph.D., Research Manager, Skin Health, Consumer Health R&D -
ON NOW
Menas Kizoulis, Director, Consumer HealthMenas Kizoulis, Director, Consumer Health -
ON NOW
Dianne Rossetti, Principal ScientistDianne Rossetti, Principal Scientist -
ON NOW
Michael Southall, Ph.D., Research Director, FellowMichael Southall, Ph.D., Research Director, Fellow
EMBOTRAP® II Revascularization Device
A team determined to improve the odds for patients suffering an ischemic stroke developed the EMBOTRAP® II Revascularization Device: an innovative stent retriever that allows physicians to capture and remove life-threatening blood clots from the brain.
-
ON NOW
Brendan Casey, Senior R&D Technical Manager, Cerenovus Galway Neuro Technology CenterBrendan Casey, Senior R&D Technical Manager, Cerenovus Galway Neuro Technology Center -
ON NOW
Mairsíl Claffey, Director, Clinical Science and Strategy, Ischemic Stroke, CerenovusMairsíl Claffey, Director, Clinical Science and Strategy, Ischemic Stroke, Cerenovus -
ON NOW
Michael Gilvarry, General Manager, Cerenovus GalwayMichael Gilvarry, General Manager, Cerenovus Galway -
ON NOW
David Vale, Chief Technology Officer, Cerenovus Galway Neuro Technology Center / CSS / OneMDDavid Vale, Chief Technology Officer, Cerenovus Galway Neuro Technology Center / CSS / OneMD
SURGICEL® Powder Absorbable Hemostat
This team of scientists, engineers, designers and clinicians from Ethicon worked together for more than eight years to create an innovative product that stops disruptive bleeding during surgery.
-
ON NOW
Alex Kiturkes, Systems Engineering Manager, Robotics & Digital SolutionsAlex Kiturkes, Systems Engineering Manager, Robotics & Digital Solutions -
ON NOW
Richard Kocharian, Ph.D., M.D., Senior Franchise Medical Director, Medical AffairsRichard Kocharian, Ph.D., M.D., Senior Franchise Medical Director, Medical Affairs -
ON NOW
Melinda MacDonald, Ph.D., DVM, Principal Scientist, PreclinicalMelinda MacDonald, Ph.D., DVM, Principal Scientist, Preclinical -
ON NOW
Jared Schneider, Staff Industrial Designer, IDHFJared Schneider, Staff Industrial Designer, IDHF -
ON NOW
Allen Y. Wang, Ph.D., Principal Scientist, Biosurgery R&DAllen Y. Wang, Ph.D., Principal Scientist, Biosurgery R&D
TREMFYA® (guselkumab)
Janssen researchers transformed the understanding of psoriasis when they realized they could leverage the body’s own immune system to treat the skin condition. A 16-year journey harnessed the latest scientific advances in immunology to deliver TREMFYA® (guselkumab).
-
ON NOW
Jacqueline Benson, Ph.D., Vice President, Immunology Scientific InnovationJacqueline Benson, Ph.D., Vice President, Immunology Scientific Innovation -
ON NOW
Mark Cunningham, Senior Director, Janssen R&D Business Operations StrategyMark Cunningham, Senior Director, Janssen R&D Business Operations Strategy -
ON NOW
M. Merle Elloso, Ph.D., Scientific Communication Lead, Janssen PharmaceuticalsM. Merle Elloso, Ph.D., Scientific Communication Lead, Janssen Pharmaceuticals -
ON NOW
Yevgeniya Orlovsky, Senior Scientist, Janssen R&DYevgeniya Orlovsky, Senior Scientist, Janssen R&D -
ON NOW
Philippe Szapary, M.D., Clinical Leader, Lung Cancer InitiativePhilippe Szapary, M.D., Clinical Leader, Lung Cancer Initiative -
ON NOW
Yasmine Wasfi, Ph.D., M.D., Senior Director, Clinical Development, Lung Cancer InitiativeYasmine Wasfi, Ph.D., M.D., Senior Director, Clinical Development, Lung Cancer Initiative
The Johnson Medal for Research and Development is named after the late General Robert Wood Johnson and is the most prestigious award given for research and development excellence within Johnson & Johnson. Through the Johnson Medal Program, we recognize the talented and dedicated individuals in our R&D organizations who are responsible for the innovative ideas that fuel our growth and commercial success.
We launched Champions of Science®, a multifaceted initiative, to convene and catalyze champions of science and engage people of all generations and backgrounds to see the unlimited opportunities that science brings.